share_log

Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales...

Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales...

Karyopharm Therapeutics宣佈在2025年下半年預計發佈針對JAKi-naïve骨髓纖維化的Selinexor的3期SENTRY試驗數據;預計在2025年上半年完成入組;Lori Macomber被任命爲財務長;2024年初步營業收入預計爲14500萬美元及XPOVIO銷量...
Benzinga ·  01/13 14:02

Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales Reached $113M

Karyopharm Therapeutics宣佈了針對JAKi-Naïve骨髓纖維化的Selinexor的第三階段SENTRY試驗數據,預計將在2025年下半年發佈;2025年上半年完成入組;Lori Macomber被任命爲財務長;2024年初步營業收入爲14500萬美元,XPOVIO銷售額達到1.13億美元

– Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 –

– 有機會通過第三階段SENTRY試驗評估Selinexor與Ruxolitinib聯合治療JAKi-Naïve骨髓纖維化患者的頂線數據解讀,定義新的骨髓纖維化治療範式,預計將在2025年下半年公佈;公司計劃在2025年上半年完成入組 –

– Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications –

– 最近宣佈了關鍵的領導變化,包括任命Lori Macomber爲財務長以及Brendan Strong爲投資者關係和企業通信的高級副總裁 –

– Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively –

– 2024年初步未經審計的全年總營業收入和美國XPOVIO(selinexor)淨產品營收預計分別爲約14500萬美元和11300萬美元 –

NEWTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.

馬薩諸塞州牛頓,2025年1月13日 /PRNewswire/ -- Karyopharm Therapeutics Inc.(納斯達克:KPTI),一家在商業階段的藥品公司,開創了新型癌症療法,今天宣佈了2024年第四季度和全年總營業收入及美國XPOVIO淨產品營收的初步未經審計估計,並概述了其2024年的成就和2025年的目標。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
評論 評論 · 瀏覽 308

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。 Moomoo將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。